APOLLON GENEVAX VACCINE TO ENTER CLINIC IN MAY FOR HIV AND T CELL LYMPHOMA; "GENERIC" MANUFACTURING PROVIDES INEXPENSIVE SUPPLY OF GENE THERAPY PRODUCT
Executive Summary
Clinical trials of facilitated DNA Genevax products for HIV infection and T cell lymphoma could begin by the end of May, according to the corporate sponsor, Apollon, Inc. The Malvern, Penn.-based firm filed INDs in late 1994 for Genevax products for the two indications. Genevax vaccine products use specific sequences of DNA to elicit responses from the immune system when injected intramuscularly.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth